<?xml version='1.0' encoding='utf-8'?>
<document id="21692601"><sentence text="Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers."><entity charOffset="10-20" id="DDI-PubMed.21692601.s1.e0" text="ticagrelor" /><entity charOffset="48-66" id="DDI-PubMed.21692601.s1.e1" text="ethinyl oestradiol" /><entity charOffset="71-85" id="DDI-PubMed.21692601.s1.e2" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.21692601.s1.e0" e2="DDI-PubMed.21692601.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21692601.s1.e0" e2="DDI-PubMed.21692601.s1.e1" /><pair ddi="false" e1="DDI-PubMed.21692601.s1.e0" e2="DDI-PubMed.21692601.s1.e2" /><pair ddi="false" e1="DDI-PubMed.21692601.s1.e1" e2="DDI-PubMed.21692601.s1.e1" /><pair ddi="false" e1="DDI-PubMed.21692601.s1.e1" e2="DDI-PubMed.21692601.s1.e2" /></sentence><sentence text="Cytochrome P450 3 A is involved in ticagrelor and ethinyl oestradiol/levonorgestrel metabolism; so a potential drug-drug interaction may occur"><entity charOffset="50-68" id="DDI-PubMed.21692601.s2.e0" text="ethinyl oestradiol" /><entity charOffset="69-83" id="DDI-PubMed.21692601.s2.e1" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.21692601.s2.e0" e2="DDI-PubMed.21692601.s2.e0" /><pair ddi="false" e1="DDI-PubMed.21692601.s2.e0" e2="DDI-PubMed.21692601.s2.e1" /></sentence><sentence text="" /><sentence text="To assess: ticagrelor effects on ethinyl oestradiol/levonorgestrel pharmacokinetics, endogenous sex hormone levels; ethinyl oestradiol/levonorgestrel effects on ticagrelor pharmacokinetics; tolerability of ticagrelor + ethinyl oestradiol/levonorgestrel"><entity charOffset="11-21" id="DDI-PubMed.21692601.s4.e0" text="ticagrelor" /><entity charOffset="33-51" id="DDI-PubMed.21692601.s4.e1" text="ethinyl oestradiol" /><entity charOffset="52-66" id="DDI-PubMed.21692601.s4.e2" text="levonorgestrel" /><entity charOffset="116-134" id="DDI-PubMed.21692601.s4.e3" text="ethinyl oestradiol" /><entity charOffset="135-149" id="DDI-PubMed.21692601.s4.e4" text="levonorgestrel" /><entity charOffset="206-237" id="DDI-PubMed.21692601.s4.e5" text="ticagrelor + ethinyl oestradiol" /><entity charOffset="238-252" id="DDI-PubMed.21692601.s4.e6" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e0" e2="DDI-PubMed.21692601.s4.e0" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e0" e2="DDI-PubMed.21692601.s4.e1" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e0" e2="DDI-PubMed.21692601.s4.e2" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e0" e2="DDI-PubMed.21692601.s4.e3" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e0" e2="DDI-PubMed.21692601.s4.e4" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e0" e2="DDI-PubMed.21692601.s4.e5" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e0" e2="DDI-PubMed.21692601.s4.e6" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e1" e2="DDI-PubMed.21692601.s4.e1" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e1" e2="DDI-PubMed.21692601.s4.e2" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e1" e2="DDI-PubMed.21692601.s4.e3" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e1" e2="DDI-PubMed.21692601.s4.e4" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e1" e2="DDI-PubMed.21692601.s4.e5" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e1" e2="DDI-PubMed.21692601.s4.e6" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e2" e2="DDI-PubMed.21692601.s4.e2" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e2" e2="DDI-PubMed.21692601.s4.e3" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e2" e2="DDI-PubMed.21692601.s4.e4" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e2" e2="DDI-PubMed.21692601.s4.e5" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e2" e2="DDI-PubMed.21692601.s4.e6" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e3" e2="DDI-PubMed.21692601.s4.e3" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e3" e2="DDI-PubMed.21692601.s4.e4" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e3" e2="DDI-PubMed.21692601.s4.e5" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e3" e2="DDI-PubMed.21692601.s4.e6" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e4" e2="DDI-PubMed.21692601.s4.e4" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e4" e2="DDI-PubMed.21692601.s4.e5" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e4" e2="DDI-PubMed.21692601.s4.e6" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e5" e2="DDI-PubMed.21692601.s4.e5" /><pair ddi="false" e1="DDI-PubMed.21692601.s4.e5" e2="DDI-PubMed.21692601.s4.e6" /></sentence><sentence text="" /><sentence text="This trial was a randomized, double-blind, two-way crossover, single-center study" /><sentence text=" Twenty-two healthy female volunteers (on stable ethinyl oestradiol/levonorgestrel) received 90 mg ticagrelor or placebo twice daily with ethinyl oestradiol/levonorgestrel (0"><entity charOffset="49-67" id="DDI-PubMed.21692601.s7.e0" text="ethinyl oestradiol" /><entity charOffset="68-82" id="DDI-PubMed.21692601.s7.e1" text="levonorgestrel" /><entity charOffset="99-109" id="DDI-PubMed.21692601.s7.e2" text="ticagrelor" /><entity charOffset="138-156" id="DDI-PubMed.21692601.s7.e3" text="ethinyl oestradiol" /><entity charOffset="157-171" id="DDI-PubMed.21692601.s7.e4" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.21692601.s7.e0" e2="DDI-PubMed.21692601.s7.e0" /><pair ddi="false" e1="DDI-PubMed.21692601.s7.e0" e2="DDI-PubMed.21692601.s7.e1" /><pair ddi="false" e1="DDI-PubMed.21692601.s7.e0" e2="DDI-PubMed.21692601.s7.e2" /><pair ddi="false" e1="DDI-PubMed.21692601.s7.e0" e2="DDI-PubMed.21692601.s7.e3" /><pair ddi="false" e1="DDI-PubMed.21692601.s7.e0" e2="DDI-PubMed.21692601.s7.e4" /><pair ddi="false" e1="DDI-PubMed.21692601.s7.e1" e2="DDI-PubMed.21692601.s7.e1" /><pair ddi="false" e1="DDI-PubMed.21692601.s7.e1" e2="DDI-PubMed.21692601.s7.e2" /><pair ddi="false" e1="DDI-PubMed.21692601.s7.e1" e2="DDI-PubMed.21692601.s7.e3" /><pair ddi="false" e1="DDI-PubMed.21692601.s7.e1" e2="DDI-PubMed.21692601.s7.e4" /><pair ddi="false" e1="DDI-PubMed.21692601.s7.e2" e2="DDI-PubMed.21692601.s7.e2" /><pair ddi="false" e1="DDI-PubMed.21692601.s7.e2" e2="DDI-PubMed.21692601.s7.e3" /><pair ddi="false" e1="DDI-PubMed.21692601.s7.e2" e2="DDI-PubMed.21692601.s7.e4" /><pair ddi="false" e1="DDI-PubMed.21692601.s7.e3" e2="DDI-PubMed.21692601.s7.e3" /><pair ddi="false" e1="DDI-PubMed.21692601.s7.e3" e2="DDI-PubMed.21692601.s7.e4" /></sentence><sentence text="03 mg/0" /><sentence text="15 mg; Nordette) on cycle days 1-21" /><sentence text=" Volunteers crossed over treatment on day 1/cycle 2" /><sentence text=" Pharmacokinetic parameters were evaluated on cycle day 21, and endogenous hormones assayed on cycle days 1, 7, 14 and 21" /><sentence text="" /><sentence text="NCT006895906" /><sentence text="" /><sentence text="Ethinyl oestradiol absorption was rapid (median t(max) approximately 1 hour), and was not affected by ticagrelor"><entity charOffset="0-18" id="DDI-PubMed.21692601.s15.e0" text="Ethinyl oestradiol" /></sentence><sentence text=" Ticagrelor co-administration (90% confidence interval [CI]) increased AUC(0-τ), C(min), and C(max) of ethinyl oestradiol by 20% (1"><entity charOffset="1-11" id="DDI-PubMed.21692601.s16.e0" text="Ticagrelor" /><entity charOffset="103-121" id="DDI-PubMed.21692601.s16.e1" text="ethinyl oestradiol" /><pair ddi="false" e1="DDI-PubMed.21692601.s16.e0" e2="DDI-PubMed.21692601.s16.e0" /><pair ddi="false" e1="DDI-PubMed.21692601.s16.e0" e2="DDI-PubMed.21692601.s16.e1" /></sentence><sentence text="03-1" /><sentence text="40), 20% (0" /><sentence text="96-1" /><sentence text="50) and 31% (1" /><sentence text="18-1" /><sentence text="44), respectively" /><sentence text=" Ticagrelor had no effect on levonorgestrel pharmacokinetic parameters versus placebo (90% CI: AUC(0-τ) 0"><entity charOffset="1-11" id="DDI-PubMed.21692601.s23.e0" text="Ticagrelor" /><entity charOffset="29-43" id="DDI-PubMed.21692601.s23.e1" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.21692601.s23.e0" e2="DDI-PubMed.21692601.s23.e0" /><pair ddi="false" e1="DDI-PubMed.21692601.s23.e0" e2="DDI-PubMed.21692601.s23.e1" /></sentence><sentence text="97-1" /><sentence text="10; C(min) 0" /><sentence text="94-1" /><sentence text="10; C(max) 1" /><sentence text="02-1" /><sentence text="16)" /><sentence text=" Steady-state ticagrelor, and AR-C124910XX (major and equally pharmacologically active metabolite), AUC(0-τ), C(max), and t(max) were comparable with published findings"><entity charOffset="14-24" id="DDI-PubMed.21692601.s30.e0" text="ticagrelor" /><entity charOffset="30-42" id="DDI-PubMed.21692601.s30.e1" text="AR-C124910XX" /><pair ddi="false" e1="DDI-PubMed.21692601.s30.e0" e2="DDI-PubMed.21692601.s30.e0" /><pair ddi="false" e1="DDI-PubMed.21692601.s30.e0" e2="DDI-PubMed.21692601.s30.e1" /></sentence><sentence text=" Pre-dose ticagrelor and AR-C124910XX plasma concentrations were higher on cycle day 21 versus days 7 and 14" /><sentence text=" Endogenous sex hormone plasma levels were unaffected by ticagrelor" /><sentence text=" Co-administration of ticagrelor with ethinyl oestradiol/levonorgestrel was well tolerated"><entity charOffset="22-32" id="DDI-PubMed.21692601.s33.e0" text="ticagrelor" /><entity charOffset="38-56" id="DDI-PubMed.21692601.s33.e1" text="ethinyl oestradiol" /><entity charOffset="57-71" id="DDI-PubMed.21692601.s33.e2" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.21692601.s33.e0" e2="DDI-PubMed.21692601.s33.e0" /><pair ddi="false" e1="DDI-PubMed.21692601.s33.e0" e2="DDI-PubMed.21692601.s33.e1" /><pair ddi="false" e1="DDI-PubMed.21692601.s33.e0" e2="DDI-PubMed.21692601.s33.e2" /><pair ddi="false" e1="DDI-PubMed.21692601.s33.e1" e2="DDI-PubMed.21692601.s33.e1" /><pair ddi="false" e1="DDI-PubMed.21692601.s33.e1" e2="DDI-PubMed.21692601.s33.e2" /></sentence><sentence text=" Study limitations included: no ticagrelor-only arm; only one type of oral contraceptive; short study duration; using oestradiol/levonorgestrel pharmacokinetic parameters as surrogate marker for contraceptive efficacy"><entity charOffset="32-42" id="DDI-PubMed.21692601.s34.e0" text="ticagrelor" /><entity charOffset="118-128" id="DDI-PubMed.21692601.s34.e1" text="oestradiol" /><entity charOffset="129-143" id="DDI-PubMed.21692601.s34.e2" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.21692601.s34.e0" e2="DDI-PubMed.21692601.s34.e0" /><pair ddi="false" e1="DDI-PubMed.21692601.s34.e0" e2="DDI-PubMed.21692601.s34.e1" /><pair ddi="false" e1="DDI-PubMed.21692601.s34.e0" e2="DDI-PubMed.21692601.s34.e2" /><pair ddi="false" e1="DDI-PubMed.21692601.s34.e1" e2="DDI-PubMed.21692601.s34.e1" /><pair ddi="false" e1="DDI-PubMed.21692601.s34.e1" e2="DDI-PubMed.21692601.s34.e2" /></sentence><sentence text="" /><sentence text="Ticagrelor co-administration with ethinyl oestradiol/levonorgestrel increased ethinyl oestradiol exposure by approximately 20%, with no effect on levonorgestrel pharmacokinetics"><entity charOffset="0-10" id="DDI-PubMed.21692601.s36.e0" text="Ticagrelor" /><entity charOffset="34-52" id="DDI-PubMed.21692601.s36.e1" text="ethinyl oestradiol" /><entity charOffset="53-67" id="DDI-PubMed.21692601.s36.e2" text="levonorgestrel" /><entity charOffset="78-96" id="DDI-PubMed.21692601.s36.e3" text="ethinyl oestradiol" /><entity charOffset="146-160" id="DDI-PubMed.21692601.s36.e4" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.21692601.s36.e0" e2="DDI-PubMed.21692601.s36.e0" /><pair ddi="false" e1="DDI-PubMed.21692601.s36.e0" e2="DDI-PubMed.21692601.s36.e1" /><pair ddi="false" e1="DDI-PubMed.21692601.s36.e0" e2="DDI-PubMed.21692601.s36.e2" /><pair ddi="false" e1="DDI-PubMed.21692601.s36.e0" e2="DDI-PubMed.21692601.s36.e3" /><pair ddi="false" e1="DDI-PubMed.21692601.s36.e0" e2="DDI-PubMed.21692601.s36.e4" /><pair ddi="false" e1="DDI-PubMed.21692601.s36.e1" e2="DDI-PubMed.21692601.s36.e1" /><pair ddi="false" e1="DDI-PubMed.21692601.s36.e1" e2="DDI-PubMed.21692601.s36.e2" /><pair ddi="false" e1="DDI-PubMed.21692601.s36.e1" e2="DDI-PubMed.21692601.s36.e3" /><pair ddi="false" e1="DDI-PubMed.21692601.s36.e1" e2="DDI-PubMed.21692601.s36.e4" /><pair ddi="false" e1="DDI-PubMed.21692601.s36.e2" e2="DDI-PubMed.21692601.s36.e2" /><pair ddi="false" e1="DDI-PubMed.21692601.s36.e2" e2="DDI-PubMed.21692601.s36.e3" /><pair ddi="false" e1="DDI-PubMed.21692601.s36.e2" e2="DDI-PubMed.21692601.s36.e4" /><pair ddi="false" e1="DDI-PubMed.21692601.s36.e3" e2="DDI-PubMed.21692601.s36.e3" /><pair ddi="false" e1="DDI-PubMed.21692601.s36.e3" e2="DDI-PubMed.21692601.s36.e4" /></sentence><sentence text=" No clinically relevant effect on contraceptive efficacy is expected with ethinyl oestradiol/levonorgestrel and ticagrelor co-administration"><entity charOffset="74-92" id="DDI-PubMed.21692601.s37.e0" text="ethinyl oestradiol" /><entity charOffset="93-107" id="DDI-PubMed.21692601.s37.e1" text="levonorgestrel" /><entity charOffset="112-122" id="DDI-PubMed.21692601.s37.e2" text="ticagrelor" /><pair ddi="false" e1="DDI-PubMed.21692601.s37.e0" e2="DDI-PubMed.21692601.s37.e0" /><pair ddi="false" e1="DDI-PubMed.21692601.s37.e0" e2="DDI-PubMed.21692601.s37.e1" /><pair ddi="false" e1="DDI-PubMed.21692601.s37.e0" e2="DDI-PubMed.21692601.s37.e2" /><pair ddi="false" e1="DDI-PubMed.21692601.s37.e1" e2="DDI-PubMed.21692601.s37.e1" /><pair ddi="false" e1="DDI-PubMed.21692601.s37.e1" e2="DDI-PubMed.21692601.s37.e2" /></sentence><sentence text="" /></document>